[Federal Register Volume 63, Number 119 (Monday, June 22, 1998)]
[Notices]
[Pages 33940-33941]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-16425]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing: Novel 
Antitumor Macrocyclic Lactones, Compositions and Methods of Use

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health is seeking licensees for the 
further development, evaluation and commercialization of materials and 
methods for novel cancer treatment agents. The invention claimed in 
DHHS Reference No. E-244-97/0, ``Novel Antitumor Macrocyclic Lactones, 
Compositions and Methods of Use,'' (Boyd, M. et al.) filed on 29 June 
1997 as USSN 60/053,784, is available for licensing (in accordance with 
35 USC 207 and 37 CFR Part 404).

ADDRESSES: Questions about the licensing opportunity should be 
addressed to Girish C. Barua, Ph.D., Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; Telephone: 301/496-7056 ext. 263; Fax: 
301/402-0220.

SUPPLEMENTARY INFORMATION: The invention relates to a series of 
macrocyclic lactones based on compounds isolated from certain marine 
sponges and tunicates. These compounds have in vitro activity against 
certain human solid tumors, including non-small cell lung cancer, renal 
cancer and melanoma, all important killers which are resistant to 
currently used drugs.
    Of particular interest is the cell-line activity profile of these 
lactones, which indicates a novel mechanism of action. Such compounds 
hold the promise of in

[[Page 33941]]

vivo activities unlike those seen with current drugs. These lactones 
thus have the potential for use as therapeutics alone or in combination 
with existing drugs.
    Information about the patent application and pertinent information 
not yet publicly described can be obtained under a Confidential 
Disclosure Agreement. Respondees interested in licensing the invention 
will be required to submit an Application for License to Public Health 
Service Inventions.

    Dated: June 16, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 98-16425 Filed 6-19-98; 8:45 am]
BILLING CODE 4140-01-M